Targeted Therapy Branch, Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang 10408, Korea.
Mol Cells. 2022 Sep 30;45(9):631-639. doi: 10.14348/molcells.2022.2037. Epub 2022 Jun 14.
Breast cancer is the leading cause of cancer-related death in women worldwide, despite medical and technological advancements. The RhoBTB family consists of three isoforms: RhoBTB1, RhoBTB2, and RhoBTB3. RhoBTB1 and RhoBTB2 have been proposed as tumor suppressors in breast cancer. However, the roles of RhoBTB3 proteins are unknown in breast cancer. Bioinformatics analysis, including Oncomine, cBioportal, was used to evaluate the potential functions and prognostic values of RhoBTB3 and Col1a1 in breast cancer. qRT-PCR analysis and immunoblotting assay were performed to investigate relevant expression. Functional experiments including proliferation assay, invasion assay, and flow cytometry assay were conducted to determine the role of RhoBTB3 and Col1a1 in breast cancer cells. RhoBTB3 mRNA levels were significantly up-regulated in breast cancer tissues as compared to in adjacent normal tissues. Moreover, RhoBTB3 expression was found to be associated with Col1a1 expression. Decreasing RhoBTB3 expression may lead to decreases in the proliferative and invasive properties of breast cancer cells. Further, Col1a1 knockdown in breast cancer cells limited the proliferative and invasive ability of cancer cells. Knockdown of RhoBTB3 may exert inhibit the proliferation, migration, and metastasis of breast cancer cells by repressing the expression of Col1a1, providing a novel therapeutic strategy for treating breast cancer.
尽管医学和技术取得了进步，但乳腺癌仍是全球女性癌症相关死亡的主要原因。RhoBTB 家族由三个同工型组成：RhoBTB1、RhoBTB2 和 RhoBTB3。RhoBTB1 和 RhoBTB2 已被提议作为乳腺癌的肿瘤抑制因子。然而，RhoBTB3 蛋白在乳腺癌中的作用尚不清楚。生物信息学分析，包括 Oncomine、cBioportal，用于评估 RhoBTB3 和 Col1a1 在乳腺癌中的潜在功能和预后价值。qRT-PCR 分析和免疫印迹分析用于研究相关表达。功能实验包括增殖实验、侵袭实验和流式细胞术实验，以确定 RhoBTB3 和 Col1a1 在乳腺癌细胞中的作用。与相邻正常组织相比，乳腺癌组织中 RhoBTB3 mRNA 水平显著上调。此外，RhoBTB3 表达与 Col1a1 表达相关。降低 RhoBTB3 表达可能导致乳腺癌细胞增殖和侵袭特性下降。此外，在乳腺癌细胞中敲低 Col1a1 会限制癌细胞的增殖和侵袭能力。敲低 RhoBTB3 可能通过抑制 Col1a1 的表达来抑制乳腺癌细胞的增殖、迁移和转移，为治疗乳腺癌提供了一种新的治疗策略。
